
Daniel E Furst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1368591/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. Rheumatology, 2023, 62, 565-574.	1.9	6
2	New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care and Research, 2023, 75, 975-982.	3.4	17
3	Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Annals of the Rheumatic Diseases, 2022, 81, e192-e192.	0.9	20
4	Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. Arthritis Care and Research, 2022, 74, 1477-1483.	3.4	1
5	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology, 2022, 61, 1385-1395.	1.9	10
6	The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort. Journal of Scleroderma and Related Disorders, 2022, 7, 117-127.	1.7	3
7	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32.	1.7	25
8	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 674-684.	5.6	57
9	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology, 2022, 61, 4155-4162.	1.9	8
10	Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 649-661.	2.3	1
11	<scp>Adiposeâ€Derived</scp> Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis and Rheumatology, 2022, 74, 1399-1408.	5.6	9
12	Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 435-446.	2.3	4
13	Examination of the Validity of Skin Ultrasound to Quantitate Skin Involvement for Multicenter Clinical Trials in Patients with Systemic Sclerosis (<scp>SSc</scp>): A Systematic Literature Review () Tj ETQq1	1 0.7 8431	4 œBT /Ov∈
14	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 2022, 62, 234-242.	1.9	13
15	Predictive model of risk and severity of enteritis in systemic lupus erythematosus. Lupus, 2022, 31, 1226-1236.	1.6	5
16	Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique study. Disability and Rehabilitation, 2021, 43, 3339-3346.	1.8	12
17	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. Annals of the Rheumatic Diseases, 2021, 80, 242-249.	0.9	6
18	Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SScAcohorts. Clinical Rheumatology, 2021, 40, 2277-2284.	2.2	11

#	Article	IF	CITATIONS
19	The role of ultrasound in systemic sclerosis: On the cutting edge to foster clinical and research advancement. Journal of Scleroderma and Related Disorders, 2021, 6, 123-132.	1.7	20
20	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Research and Therapy, 2021, 23, 51.	3.5	18
21	Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population—a multicentre study. Rheumatology, 2021, 60, 5142-5148.	1.9	11
22	Trend in women representation among authors of high rank rheumatology journals articles, 2002–2019. Rheumatology, 2021, 60, 5127-5133.	1.9	1
23	Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients. Journal of Scleroderma and Related Disorders, 2021, 6, 236-241.	1.7	1
24	Pharmacokinetic equivalence of CTâ€P17 to highâ€concentration (100Âmg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clinical and Translational Science, 2021, 14, 1280-1291.	3.1	11
25	Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps. Seminars in Arthritis and Rheumatism, 2021, 51, 425-429.	3.4	2
26	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CTâ€P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. British Journal of Clinical Pharmacology, 2021, 87, 4323-4333.	2.4	7
27	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. Seminars in Arthritis and Rheumatism, 2021, 51, 601-606.	3.4	7
28	The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. Arthritis Research and Therapy, 2021, 23, 212.	3.5	16
29	Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. BMJ Open, 2021, 11, e049850.	1.9	Ο
30	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care and Research, 2021, , .	3.4	3
31	Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. , 2021, 8, 120-129.		5
32	Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis. Rheumatology and Therapy, 2021, 8, 1637-1649.	2.3	16
33	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. Arthritis Research and Therapy, 2021, 23, 10.	3.5	18
34	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 124-133.	0.8	1
35	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and Experimental Rheumatology, 2021, 39, 124-133.	0.8	11
36	Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. Journal of Rheumatology, 2020, 47, 881-887.	2.0	32

#	Article	IF	CITATIONS
37	Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 7-11.	3.4	6
38	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>II</scp> Investigatorâ€Initiated, Multicenter, Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	5.6	163
39	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Annals of the Rheumatic Diseases, 2020, 79, 88-93.	0.9	63
40	Evaluation of cognitive function in systemic sclerosis patients: a pilot study. Clinical Rheumatology, 2020, 39, 1551-1559.	2.2	12
41	Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study. Journal of Scleroderma and Related Disorders, 2020, 5, 143-151.	1.7	3
42	Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease. Rheumatology, 2020, 59, 2024-2029.	1.9	21
43	Preliminary study of the association of serum irisin levels with poor sleep quality in rheumatoid arthritis patients. Sleep Medicine, 2020, 67, 71-76.	1.6	14
44	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	3.9	34
45	Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach. Journal of Scleroderma and Related Disorders, 2020, 5, 231-236.	1.7	2
46	Machine learning predicts stem cell transplant response in severe scleroderma. Annals of the Rheumatic Diseases, 2020, 79, 1608-1615.	0.9	29
47	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.9	51
48	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 963-967.	3.4	3
49	Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety, 2020, 19, 935-944.	2.4	8
50	Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial. Rheumatology and Therapy, 2020, 7, 327-344.	2.3	25
51	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. Annals of the Rheumatic Diseases, 2020, 79, 1269-1276.	0.9	3
52	Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 161-168.	0.8	5
53	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Annals of the Rheumatic Diseases, 2019, 78, 1371-1378.	0.9	43
54	Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use. Drug Safety, 2019, 42, 1499-1506.	3.2	9

Daniel E Furst

#	Article	IF	CITATIONS
55	The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. European Journal of Internal Medicine, 2019, 70, 43-49.	2.2	7
56	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	2.0	11
57	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis and Rheumatology, 2019, 71, 2059-2067.	5.6	55
58	Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 135.	3.5	27
59	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2019, , .	1.9	0
60	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. Journal of Rheumatology, 2019, 46, 1173-1178.	2.0	6
61	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open, 2019, 5, e000840.	3.8	8
62	Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters. Arthritis Research and Therapy, 2019, 21, 95.	3.5	8
63	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. Journal of Rheumatology, 2019, 46, 1316-1325.	2.0	23
64	Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and management. Clinical Immunology, 2019, 202, 59-75.	3.2	10
65	Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review. Clinical Rheumatology, 2019, 38, 1433-1436.	2.2	4
66	THU0170â€A MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM DATA FROM THE OPEN-LABEL TREATMENT PERIOD. , 2019, , .		0
67	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology, 2019, 58, 874-883.	1.9	16
68	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of the Rheumatic Diseases, 2019, 78, 122-130.	0.9	141
69	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. Journal of Rheumatology, 2019, 46, 603-608.	2.0	16
70	Imaging and serum biomarkers in connective tissue disease–associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels. Annals of the Rheumatic Diseases, 2019, 78, 573-575.	0.9	9
71	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism, 2019, 48, 958-966.	3.4	9
72	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36

Daniel E Furst

#	Article	IF	CITATIONS
73	Timely renal transplantation for scleroderma end-stage kidney disease patients can improve outcomes and quality of life. Annals of Translational Medicine, 2019, 7, 60-60.	1.7	5
74	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine, 2018, 378, 35-47.	27.0	417
75	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clinical Rheumatology, 2018, 37, 2331-2340.	2.2	22
76	Ultrasound characterization of cutaneous ulcers in systemic sclerosis. Clinical Rheumatology, 2018, 37, 1555-1561.	2.2	34
77	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo ontrolled Trials. Arthritis Care and Research, 2018, 70, 439-444.	3.4	53
78	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). American Journal of Respiratory and Critical Care Medicine, 2018, 197, 644-652.	5.6	77
79	Etiology unknown: Qualitative analysis of patient attributions of causality in scleroderma. Journal of Scleroderma and Related Disorders, 2018, 3, 182-188.	1.7	0
80	Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity. Clinical Rheumatology, 2018, 37, 3239-3246.	2.2	19
81	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Rheumatology International, 2018, 38, 2225-2231.	3.0	4
82	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. Frontiers in Immunology, 2018, 9, 2045.	4.8	67
83	High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference. Arthritis Research and Therapy, 2018, 20, 181.	3.5	40
84	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS ONE, 2018, 13, e0189498.	2.5	25
85	Validation of Sonography findings of synovitis and tenosynovitis of hands and wrists in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2018, 3, 228-236.	1.7	2
86	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	1.9	53
87	Examining the validity of the rheumatoid arthritis magnetic resonance imaging score according to the OMERACT filter—a systematic literature review. Rheumatology, 2017, 56, 1177-1188.	1.9	23
88	Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. Journal of Rheumatology, 2017, 44, 795-798.	2.0	0
89	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2017, 56, 1302-1311.	1.9	51
90	High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis. Seminars in Arthritis and Rheumatism, 2017, 47, 403-408.	3.4	17

#	Article	IF	CITATIONS
91	Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clinical Rheumatology, 2017, 36, 2045-2054.	2.2	27
92	Improved Cough and Cough-Specific QualityÂof Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease. Chest, 2017, 151, 813-820.	0.8	54
93	Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. Joint Bone Spine, 2017, 84, 747-748.	1.6	17
94	Points to consider when doing a trial primarily involving the heart. Rheumatology, 2017, 56, v12-v16.	1.9	6
95	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. Rheumatology, 2017, 56, v33-v37.	1.9	4
96	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology, 2017, 56, v27-v32.	1.9	23
97	Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. Rheumatology, 2017, 56, v4-v11.	1.9	6
98	Points to consider in renal involvement in systemic sclerosis. Rheumatology, 2017, 56, v49-v52.	1.9	12
99	Assessment of skin involvement in systemic sclerosis. Rheumatology, 2017, 56, v53-v66.	1.9	41
100	Points to consider—Raynaud's phenomenon in systemic sclerosis. Rheumatology, 2017, 56, v45-v48.	1.9	23
101	Points to consider for skin ulcers in systemic sclerosis. Rheumatology, 2017, 56, v67-v71.	1.9	59
102	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. Journal of Rheumatology, 2017, 44, 1536-1543.	2.0	25
103	An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group. Journal of Rheumatology, 2017, 44, 1734-1739.	2.0	9
104	Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review. Expert Review of Clinical Immunology, 2017, 13, 741-752.	3.0	10
105	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. Journal of Rheumatology, 2017, 44, 1916-1919.	2.0	11
106	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism, 2017, 46, 699-708.	3.4	19
107	Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis. Rheumatology, 2017, 56, v17-v22.	1.9	13
108	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. Rheumatology, 2017, 56, v23-v26.	1.9	9

#	Article	IF	CITATIONS
109	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 11-18.	1.7	321
110	Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. International Journal of Rheumatology, 2017, 2017, 1-15.	1.6	24
111	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120.	1.7	62
112	Clinical Pearls from the World Congress on Systemic Sclerosis, February, 2016. Journal of Scleroderma and Related Disorders, 2017, 2, 64-68.	1.7	0
113	Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation. Journal of Scleroderma and Related Disorders, 2016, 1, 7-9.	1.7	3
114	Systemic sclerosis trial design moving forward. Journal of Scleroderma and Related Disorders, 2016, 1, 177-180.	1.7	42
115	Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project. PLoS ONE, 2016, 11, e0147556.	2.5	4
116	Esophageal Surgeries in Systemic sclerosis (SSc) - A Systematic Review of the Literature. Journal of Scleroderma and Related Disorders, 2016, 1, 10-15.	1.7	2
117	Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium. Arthritis and Rheumatology, 2016, 68, 1483-1492.	5.6	90
118	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open, 2016, 2, e000225.	3.8	54
119	Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis. Scientific Reports, 2016, 6, 28793.	3.3	42
120	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1501-1505.	0.9	17
121	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2016, 315, 1975.	7.4	95
122	Premedication prevents infusion reactions and improves retention rate during infliximab treatment. Clinical Rheumatology, 2016, 35, 2841-2845.	2.2	15
123	Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. Seminars in Arthritis and Rheumatism, 2016, 46, 312-318.	3.4	28
124	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 1-25.	3.4	890
125	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	10.7	754
126	Scleroderma renal crisis and renal involvement in systemic sclerosis. Nature Reviews Nephrology, 2016, 12, 678-691.	9.6	117

#	Article	IF	CITATIONS
127	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Research and Therapy, 2016, 18, 305.	3.5	58
128	Calcinosis in systemic sclerosis: subsets, distribution and complications. Rheumatology, 2016, 55, 1610-1614.	1.9	35
129	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Research and Therapy, 2016, 18, 20.	3.5	18
130	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 374-381.	0.9	76
131	Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology, 2016, 55, 669-679.	1.9	62
132	The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis. Journal of Rheumatology, 2016, 43, 512-523.	2.0	50
133	Modified intention-to-treat analysis did not bias trial results. Journal of Clinical Epidemiology, 2016, 72, 66-74.	5.0	39
134	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. Seminars in Arthritis and Rheumatism, 2016, 45, 439-445.	3.4	23
135	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. Journal of Rheumatology, 2015, 42, 2185-2189.	2.0	40
136	Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. Rheumatology (Sunnyvale, Calif), 2015, 05, .	0.3	11
137	Management of Systemic Sclerosis-Related Skin Disease. Rheumatic Disease Clinics of North America, 2015, 41, 399-417.	1.9	17
138	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology, 2015, 54, 1369-1379.	1.9	21
139	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials. Arthritis Research and Therapy, 2015, 17, 372.	3.5	87
140	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24â€months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases, 2015, 74, 19-26.	0.9	201
141	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology, 2015, 54, 144-151.	1.9	30
142	Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. Journal of Rheumatology, 2015, 42, 1624-1630.	2.0	17
143	Antinuclear antibody-negative systemic sclerosis. Seminars in Arthritis and Rheumatism, 2015, 44, 680-686.	3.4	60
144	Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology, 2015, 54, kev249.	1.9	10

#	Article	IF	CITATIONS
145	Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. Journal of Rheumatology, 2015, 42, 1761-1766.	2.0	194
146	Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. PLoS ONE, 2015, 10, e0136982.	2.5	7
147	What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?. Clinical and Experimental Rheumatology, 2015, 33, S117-22.	0.8	7
148	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases, 2014, 73, 1607-1615.	0.9	125
149	Rheumatoid Arthritis: Are Current Research-based Guidelines Clinically Relevant?. Journal of Rheumatology, 2014, 41, 1569-1570.	2.0	2
150	Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. BMJ Open, 2014, 4, e005297-e005297.	1.9	19
151	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars in Arthritis and Rheumatism, 2014, 44, 55-62.	3.4	69
152	Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology, 2014, 53, 1560-1569.	1.9	178
153	Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. Annals of the Rheumatic Diseases, 2014, 73, 1781-1787.	0.9	21
154	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	6.2	182
155	Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums. Seminars in Arthritis and Rheumatism, 2014, 43, 458-469.	3.4	81
156	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. Seminars in Arthritis and Rheumatism, 2014, 43, 666-672.	3.4	115
157	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
158	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology, 2013, 52, 1845-1855.	1.9	28
159	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, ii2-ii34.	0.9	114
160	Medical costs and healthâ€care resource use in patients with inflammatory myopathies in an insured population. Muscle and Nerve, 2012, 46, 496-505.	2.2	17
161	Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle and Nerve, 2012, 45, 676-683.	2.2	127
162	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 32-38.	0.9	394

#	Article	IF	CITATIONS
163	Adverse Events during the Scleroderma Lung Study. American Journal of Medicine, 2011, 124, 459-467.	1.5	30
164	Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care and Research, 2011, 63, 856-864.	3.4	49
165	Rheumatoid arthritis and pregnancy: Disease activity, pregnancy outcomes, and treatment options during pregnancy and lactation. Drug Development Research, 2011, 72, 689-702.	2.9	3
166	Double-Blind, Randomized, Controlled, Pilot Study Comparing Classic Ayurvedic Medicine, Methotrexate, and Their Combination in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2011, 17, 185-192.	0.9	63
167	Rituximab for Rheumatoid Arthritis: A Meta-Analysis and Systematic Review. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S5566.	0.4	1
168	Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2010, 28, S5-12.	0.8	19
169	Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo. Chest, 2009, 136, 1333-1340.	0.8	127
170	High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease. Chest, 2008, 134, 358-367.	0.8	198
171	Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases, 2007, 66, 893-899.	0.9	96
172	Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection. Seminars in Arthritis and Rheumatism, 2006, 36, 159-167.	3.4	207
173	Tacrolimus in Patients with Rheumatoid Arthritis. Drugs, 2005, 65, 1002-1003.	10.9	0
174	A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 2303-10.	2.0	12
175	Relationships of Positive and Negative Affect to Coping and Functional Outcomes in Systemic Sclerosis. Cognitive Therapy and Research, 2004, 28, 593-610.	1.9	14
176	Anakinra: Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clinical Therapeutics, 2004, 26, 1960-1975.	2.5	155
177	Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety) Tj ETQq1 1 0.7	78 43 14 rg	(BT3¦ฌิverlock
178	Stem cell transplantation for autoimmune disease: progress and problems. Current Opinion in Rheumatology, 2002, 14, 220-224.	4.3	20
179	Disease-Modifying Antirheumatic Drugs. Drugs and Aging, 1995, 7, 420-437.	2.7	28
180	Are There Differences Among Nonsteroidal Antiinflammatory Drugs?. Arthritis and Rheumatism, 1994, 37. 1-9.	6.7	111

#	Article	IF	CITATIONS
181	Abnormalities of Renal Physiology in Systemic Sclerosis. Arthritis and Rheumatism, 1994, 37, 67-74.	6.7	45
182	Antirheumatic drugs: A proposed new classification. Arthritis and Rheumatism, 1993, 36, 336-339.	6.7	66
183	Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. Biopharmaceutics and Drug Disposition, 1988, 9, 273-283.	1.9	9
184	Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis and Rheumatism, 1985, 28, 308-314.	6.7	42
185	Low-Dose D-Penicillamine Therapy in Rheumatoid Arthritis. Arthritis and Rheumatism, 1983, 26, 581-592.	6.7	91
186	Comparison of Tolmetin Kinetics in Rheumatoid Arthritis and Matched Healthy Controls. Journal of Clinical Pharmacology, 1983, 23, 557-562.	2.0	2
187	Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 1982, 32, 371-377.	4.7	35
188	Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 1982, 31, 733-740.	4.7	91
189	Effects of Indomethacin and Carprofen on Renal Homeostasis in Rheumatoid Arthritis Patients and in Healthy Individuals. Journal of Clinical Pharmacology, 1981, 21, 493-500.	2.0	10
190	The arthropathy of advanced progressive systemic sclerosis. Arthritis and Rheumatism, 1981, 24, 874-884.	6.7	78
191	Abnormalities of Pulmonary Vascular Dynamics and Inflammation In Early Progressive Systemic Sclerosis. Arthritis and Rheumatism, 1981, 24, 1403-1408.	6.7	72
192	Steady-state serum salicylate levels in hospitalized patients with rheumatoid arthritis. Arthritis and Rheumatism, 1979, 22, 384-388.	6.7	27
193	A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. Arthritis and Rheumatism, 1979, 22, 904-910.	6.7	111
194	Salicylate clearance, the resultant of protein binding and metabolism. Clinical Pharmacology and Therapeutics, 1979, 26, 380-389.	4.7	74
195	Association of HLA Antigen A9 with Progressive Systemic Sclerosis (Scleroderma). Tissue Antigens, 1978, 11, 357-361.	1.0	40
196	Muscle disease in progressive systemic sclerosis. diagnostic and therapeutic considerations. Arthritis and Rheumatism, 1978, 21, 62-71.	6.7	170